Home » Newsletters » BioWorld Science

BioWorld Science

July 25, 2000

View Archived Issues

Genentech moves products forward in Q2 2000

BCY Ventures selects lead compound for CF therapy

Inhaled furosemide reduces experimental dyspnea in humans

Brasofensine coadministered with levodopa/carbidopa in PD patients

Phase I trial of edaravone further defines pharmacokinetic profile

Extended intervention time interval demonstrated for AM-36

Renally impaired subjects tolerate AMP-579 well, without dose adjustment

Linear pharmacokinetics, good tolerance reported for SKP-450 in healthy volunteers

Atosiban effectively and safely delays preterm birth; major European launch reported

Fujisawa seeks Canadian approval of tacrolimus ointment; FDA reschedules advisory committee meeting

Preclinical results for NCX-2216 support its development for Alzheimer's disease

SmithKline Beecham submits sNDA for Paxil for use in PTSD

Antiinflammatory drug candidate acquired by Discovery Therapeutics advances to phase II

Vion begins phase I trial of intravenous TAPET at Royal Marsden Hospital

Immunoconjugates claimed by Progenics for treatment, diagnosis of AIDS

Recently issued patent covers new Haemophilus vaccines

New allogeneic cancer vaccines in development at Onyvax

Peptides synthesized at Eisai modulate active oxygen production in neutrophils

Fujisawa presents new series of hypoglycemic agents

Compounds for beta3-adrenoceptor-related disorders designed at Asahi

Chemokine CCR3 receptor modulators claimed by DuPont in recent patent literature

Chiron halts clinical development of rhIGF-I in osteoarthritis

DPC-681 and DPC-684, new HIV protease inhibitors selected as clinical candidates

Arrow Therapeutics and Triangle Pharmaceuticals establish collaboration for antiviral agents

Neurocrine and Taisho complete final agreement; preliminary phase I data for NBI-6024 promising

Photofrin distribution agreement established

Pharmacyclics updates Xcytrin clinical trial progress

Licensing opportunity from NIH: polypeptides binding with HIV-1 gp120

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.